

PROTOCOL NUMBER	STUDY TITLE	UOC	PI / REFERENT E
<b>C2201</b>	BIO-OSCAR: Evaluation of Standard of Care Practices, Procedural Outcomes and In-hospital Complications of Peripheral Endovascular Procedures (BIO-OSCAR SOC)	CH. VASCOLARE	De Donato
<b>16521</b>	PLIANT II: Prospective Multicenter Registry to Examine the Real-world Performance of the E-liac Stent Graft System for Treatment of Uni- or Bilateral Aorto-iliac or Iliac Aneurysms	CH. VASCOLARE	De Donato
R668-CSNP-2072	R668-CSNP-2072 Regeneraon AROMA: Efficacy of Dupilumab in chronic polypoid rhinosinusitis	ORL	Mandalà
GSK219104 - SKIN	Evaluation of tonsils immunomediated response.	ORL	Mandalà
SGZ-2022-13785	Assessment of mucociliary transport time in patients with CRSwNP in treatment with Dupixent (Amulet)	ORL	Mandalà
RPC01-3001	A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in RELAPSING Multiple Sclerosis	CLIN. MAL. NEUROMET.	De Stefano
MA30143	<i>ENSEMBLE: AN OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB IN PATIENTS WITH EARLY STAGE RELAPSING REMITTING MULTIPLE SCLEROSIS</i>	CLIN. MAL. NEUROMET.	De Stefano
MN39889	<i>A multicentre non-interventional study to assess the real-world effectiveness of Ocrelizumab in patients with relapsing or primary progressive multiple sclerosis – The MuSicale STUDY</i>	CLIN. MAL. NEUROMET.	De Stefano
221AD304 – EMBARK	<i>Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (aducanumab) in Subjects With Alzheimer's Disease Who Had Previously Participated in the Aducanumab</i>	CLIN. MAL. NEUROMET.	De Stefano

	<i>Studies 221AD103, 221AD301, 221AD302, and 221AD205</i>		
GN41851 - Fenhance	<i>A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB COMPARED WITH TERIFLUNOMIDE IN ADULT PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS</i>	CLIN. MAL. NEUROMET.	De Stefano
INNODIA 01 IRAS Project ID: 210497	An Innovative approach towards understanding and arresting type 1 diabetes (INNODIA)	DIABETOLOGI A	Dotta
SELECT EX9536-4388 EUdraCT Number: 2017-003380-35	Semaglutide effects on cardiovascular outcomes in people with overweight or obesity	DIABETOLOGI A	Dotta
VER-A-T1D EUdraCT Number: 2020-000435-45	A randomised, double-blind, placebo controlled, parallel group, multi-centre trial in adult subjects with newly diagnosed type 1 diabetes mellitus investigating the effect of Verapamil SR on preservation of beta-cell function	DIABETOLOGI A	Dotta
GOLDEN AGE	Intraclass Safety and Efficacy Comparison Among SGLT-2 Inhibitors in Elderly Patients With Type 2 Diabetes. A Pragmatic, Phase IV, Multicenter, Open-label, Randomised Controlled Trial	DIABETOLOGI A	Dotta
ACHIEVE4. JA2-MC-GZGS EU trial number: 2022-502833-25-00	A Phase 3, Open-Label Study of Once Daily LY3502970 Compared with Insulin Glargine in Adult Participants with Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk	DIABETOLOGI A	Dotta
20220083	A Randomized, Double-blind Study Evaluating Pharmacokinetic Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Resected Stage III or Stage IV Melanoma Subjects in the Adjuvant Setting	IMMUNOTP. ONCOLOGICA	Maio

ACT 16845	Phase 2 non-randomized, open-label, multi-center basket study assessing the clinical benefit of SAR444245 (THOR-707) combined with cemiplimab for the treatment of participants with advanced unresectable or metastatic skin cancers	IMMUNOTP. ONCOLOGICA	Maio
ALKS4230-006	A Phase 2, Open Label, Multicenter, Cohort Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy in Patients With Advanced Cutaneous Melanoma or Advanced Mucosal Melanoma Who Have Previously Received Anti-PD-[L]-1 Therapy - ARTISTRY-6	IMMUNOTP. ONCOLOGICA	Maio
AN2025H0301	The BURAN Study of Buparlisib (AN2025) In Combination with Paclitaxel Compared to Paclitaxel Alone, in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma	IMMUNOTP. ONCOLOGICA	Maio
ANV419-101	OMNIA-1, A Phase 1/2 Study of ANV419 as Monotherapy or in Combination With Anti-PD-1 or Anti-CTLA-4 Antibody Following Anti-PD-1/Anti-PD-L1 Antibody Treatment in Patients With Unresectable or Metastatic Cutaneous Melanoma	IMMUNOTP. ONCOLOGICA	Maio
ARC-9	Phase Ib/II study to evaluate etrumadenant (AB928)-based treatment combinations in patients with metastatic colorectal cancer (mCRC).	IMMUNOTP. ONCOLOGICA	Maio
Bey Pro 2	An evaluation of the efficacy beyond progression of vemurafenib combined with cobimetinib associated with local treatment compared to second line treatment in patients with BRAFV600 mutation-positive metastatic melanoma in focal progression with first-line combined vemurafenib and cobimetinib	IMMUNOTP. ONCOLOGICA	Di Giacomo
BNT111-01	Open-label, randomized Phase II trial with BNT111 and cemiplimab in combination or as single agents in patients with anti-PD-1-	IMMUNOTP. ONCOLOGICA	Maio

	refractory/relapsed, unresectable Stage III or IV melanoma		
BNT113-01	An open label Phase II randomized trial of BNT113 in combination with pembrolizumab versus pembrolizumab monotherapy as a first line therapy in patients with unresectable recurrent, or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) which is positive for human papilloma virus 16 (HPV16+) and expresses PD-L1	IMMUNOTP. ONCOLOGICA	Maio
BO41932	Tumor-Agnostic Precision Immunooncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial	IMMUNOTP. ONCOLOGICA	Maio
BO43328	A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma)	IMMUNOTP. ONCOLOGICA	Maio
C4221016	A Phase 3, Randomized, Double-blind Study of Encorafenib and Binimetinib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab in Participants With BRAF V600E/K Mutation-Positive Metastatic OR Unresectable Locally Advanced Melanom	IMMUNOTP. ONCOLOGICA	Maio
C4221023	A phase 2, randomized, open-label study of encorafeninb and binimetinib plus pembrolizumab versus nivolumab and ipilimumab in partecipants with Braf V600E/K mutation-positive melanoma who progressed during or after prior treatment with anti-PD-1 therapy	IMMUNOTP. ONCOLOGICA	Maio
C-800-23	A multicohort, open-label, phase 2 study of Botensilimab (AGEN1181) for treatment of advanhced melanoma refractory to prior checkpoint inhibitor therapy	IMMUNOTP. ONCOLOGICA	Maio

CA022-001	Phase 1/2a First-In-Human Study of BMS-986218 Monoclonal Antibody Alone and in Combination with Nivolumab in Advanced Solid Tumors	IMMUNOTP. ONCOLOGICA	Maio
CA030-001	A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors	IMMUNOTP. ONCOLOGICA	Maio
CA052-002	A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors	IMMUNOTP. ONCOLOGICA	Maio
CA115-001	A Phase 1b/2 Study of BMS-986442 in Combination With Nivolumab or Nivolumab and Chemotherapies in Participants With Advanced Solid Tumors and Non-small Cell Lung Cancer	IMMUNOTP. ONCOLOGICA	Maio
CA120-1001	A Phase 1/2 Study of BMS-986449 Alone and in Combination With Nivolumab in Participants With Advanced Solid Tumors	IMMUNOTP. ONCOLOGICA	Maio
<b>CA209-067</b>	A Phase 3, Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab Versus Ipilimumab Monotherapy in Subjects With Previously Untreated Unresectable or Metastatic Melanoma	IMMUNOTP. ONCOLOGICA	Maio
<b>CA209-143</b>	A Randomized Phase 3 Open Label Study of Nivolumab Versus Bevacizumab and a Safety Study of Nivolumab or Nivolumab in Combination With Ipilimumab in Adult Subjects With Recurrent Glioblastoma (GBM)	IMMUNOTP. ONCOLOGICA	Maio
CA209-238	A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy with Nivolumab versus Ipilimumab after Complete Resection of Stage IIIb/c or Stage IV Melanoma in Subjects who are at High Risk for Recurrence	IMMUNOTP. ONCOLOGICA	Maio

CA209-548	A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6-methylguanine DNA methyltransferase) Glioblastoma	IMMUNOTP. ONCOLOGICA	Maio
CA209-76K	Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma	IMMUNOTP. ONCOLOGICA	Maio
CA209-76U	A Phase 1/2 Pharmacokinetic Multi-tumor Study of Subcutaneous Formulation of Ipilimumab Monotherapy and in Combination With Subcutaneous Nivolumab	IMMUNOTP. ONCOLOGICA	Maio
CA209-8FC	A Randomized, Double-Blind, Parallel, Phase 1 Study to Compare the Pharmacokinetics of BMSCHO1-Nivolumab Process D to Nivolumab Process C after Complete Resection of Stage IIIa/b/c/d or Stage IV Melanoma	IMMUNOTP. ONCOLOGICA	Maio
CA209-8TT	Pan Tumor Study for Long Term Follow-up of Cancer Survivors Who Have Participated in Trials Investigating Nivolumab	IMMUNOTP. ONCOLOGICA	Maio
CA209-915	A Phase 3, Randomized Study of Adjuvant Immunotherapy with Nivolumab Combined with Ipilimumab Versus Nivolumab Monotherapy after Complete Resection of Stage IIIb/c/d or Stage IV Melanoma	IMMUNOTP. ONCOLOGICA	Maio
CA224-047	A Randomized, Double-Blind Phase 2/3 Study of Relatlimab Combined With Nivolumab Versus Nivolumab in Participants With Previously Untreated Metastatic or Unresectable Melanoma	IMMUNOTP. ONCOLOGICA	Maio
CA224-098	A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy With Relatlimab and Nivolumab Fixed-dose Combination Versus Nivolumab Monotherapy After Complete Resection of Stage III-IV Melanoma	IMMUNOTP. ONCOLOGICA	Maio

CA224-127	A Phase 3, Randomized, Open-label, Study of Subcutaneous Nivolumab + Relatlimab Fixeddose Combination versus Intravenous Nivolumab + Relatlimab Fixed-dose Combination in Participants with Previously Untreated Metastatic or Unresectable Melanoma	IMMUNOTP. ONCOLOGICA	Maio
CA224-104	A Phase 2 Randomized Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)	IMMUNOTP. ONCOLOGICA	Maio
CA209-848	A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination With Ipilimumab or Nivolumab Monotherapy in Participants With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)	IMMUNOTP. ONCOLOGICA	Maio
CA045-001	A Phase 3, Randomized, Open-label Study of NKTR-214 Combined With Nivolumab Versus Nivolumab in Participants With Previously Untreated Unresectable or Metastatic Melanoma	IMMUNOTP. ONCOLOGICA	Maio
CA209-817	A Phase 3b/4 Safety Trial of Flat Dose Nivolumab In Combination With Ipilimumab in Participants With Non-Small Cell Lung Cancer	IMMUNOTP. ONCOLOGICA	Maio
CA209-743	A Phase III, Randomized, Open Label Trial of Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma	IMMUNOTP. ONCOLOGICA	Maio
CO39262	A Phase III, Double-Blinded, Randomized, Placebo-Controlled Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFV600 Mutation-Positive Patients With Unresectable	IMMUNOTP. ONCOLOGICA	Maio

	Locally Advanced or Metastatic Melanoma		
CPDR001F2301	A randomized, double-blind, placebo-controlled, phase III study comparing the combination of PDR001, dabrafenib and trametinib versus placebo, dabrafenib and trametinib in previously untreated patients with unresectable or metastatic BRAF V600 mutant melanoma	IMMUNOTP. ONCOLOGICA	Maio
D9108C0001	A Phase 2, Open-label, Multicenter, Randomized, Multidrug Platform Study of Durvalumab Alone or in Combination with Novel Agents in Subjects with Locally Advanced, Unresectable, Stage III Non-small Cell Lung Cancer	IMMUNOTP. ONCOLOGICA	Maio
CYP003	A Phase 1b/2a, Open-Label, Multi-Center Study of CyPep-1 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety of CyPep-1 in Patients With Advanced or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC), Melanoma, or Triple-Negative Breast Cancer (TNBC)	IMMUNOTP. ONCOLOGICA	Maio
D533AC00001	A Randomised, Open-Label, Phase 2 Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Unresectable or Advanced Melanoma and Primary or Secondary Resistance to PD-(L)1 Inhibition	IMMUNOTP. ONCOLOGICA	Maio
DZ2022E0005	A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutation	IMMUNOTP. ONCOLOGICA	Maio



EORTC 1612	Combination of targeted therapy (encorafenib and binimetinib) followed by combination of immunotherapy (ipilimumab and nivolumab) vs immediate combination of immunotherapy in patients with unresectable or metastatic melanoma with BRAF V600 mutation : an EORTC randomized phase II study (EBIN).	IMMUNOTP. ONCOLOGICA	Maio
ETOP 19-21 USZ-STRIKE	A multicentre randomised open-label phase III study of stereotactic radiosurgery, in addition to standard systemic therapy for patients with metastatic melanoma or newly diagnosed metastatic NSCLC and asymptomatic or oligo-symptomatic brain metastases.	IMMUNOTP. ONCOLOGICA	Di Giacomo
Fight-302 (INCB54828-302)	A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement (FIGHT-302)	IMMUNOTP. ONCOLOGICA	Maio
GFH925X0201	A Phase Ib/II, Multi-Center, Open-Label Study to Evaluate the Safety/Tolerability, Pharmacokinetics, and Efficacy of GFH925 in Combination with Cetuximab in Previously Untreated Advanced NSCLC Harboring KRAS G12C Mutation	IMMUNOTP. ONCOLOGICA	Maio
Gsk 205801	Protocol Title: A Phase II, Randomized, Open-label Platform Trial Utilizing a Master Protocol to Study Novel Regimens Versus Standard of Care Treatment in NSCLC Participants	IMMUNOTP. ONCOLOGICA	Maio
GSK costar 213410	A Randomized, Open-Label Phase 2/3 Study Comparing Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone In Participants with Advanced Nonsmall Cell Lung	IMMUNOTP. ONCOLOGICA	Maio

	Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy (COSTAR Lung)		
GO42784	A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Patients With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer	IMMUNOTP. ONCOLOGICA	Maio
GS-US-548-5916	A Phase 2 Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma	IMMUNOTP. ONCOLOGICA	Maio
GS-US-592-6173	Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced, Inoperable, or Metastatic Triple-Negative Breast Cancer, Whose Tumors Express PD-L1	IMMUNOTP. ONCOLOGICA	Maio
GS-US-592-6238	A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients Previously Treated With Anti-PD-(L)1 Agents in the Early Setting Whose Tumors Do Express PD-L1	IMMUNOTP. ONCOLOGICA	Maio

HBI-8000-909	A Multicenter, Randomized, Double-Blind Phase 3 Study of HBI-8000 Combined with Nivolumab versus Placebo with Nivolumab in Patients with Unresectable or Metastatic Melanoma Not Previously Treated with PD-1 or PD-L1 Inhibitors	IMMUNOTP. ONCOLOGICA	Maio
IMCgp100-203	Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination With Pembrolizumab Versus Investigator's Choice in HLA-A*02:01-positive Participants With Previously Treated Advanced Melanoma (TEBE-AM)	IMMUNOTP. ONCOLOGICA	Maio
MGC936-901	A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation and Expansion Study of IMGC936 (Anti-ADAM9 Antibody Drug Conjugate) in Patients With Advanced Solid Tumors	IMMUNOTP. ONCOLOGICA	Maio
INCMGA 0012-201	A Phase 2 Study of INCMGA00012 in Participants With Metastatic Merkel Cell Carcinoma (POD1UM-201)	IMMUNOTP. ONCOLOGICA	Maio
INCMGA 0012-203	A Phase 2 Study of INCMGA00012 (PD-1 Inhibitor) in Participants With Selected Solid Tumors (POD1UM-203)	IMMUNOTP. ONCOLOGICA	Maio
INCB86550-102	A Phase 1 Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB086550 in Participants With Advanced Solid Tumors	IMMUNOTP. ONCOLOGICA	Maio
IOA-244-101	First-in-Human Dose Study of IOA-244 alone and in combination with pemetrexed/cisplatin in patients with advanced or metastatic cancers	IMMUNOTP. ONCOLOGICA	Maio
IOA-289-102	A Phase 1b, Open Label, Dose Escalation Study of IOA-289, an Orally Bioavailable, Selective Autotaxin (ENPP2) Inhibitor Alone and in Combination With Gemcitabine/Nab-paclitaxel in Patients With Metastatic Pancreatic Cancer	IMMUNOTP. ONCOLOGICA	Maio

IOB-013: IO102-IO103-013 / MK3475-D18 (KN-D18)	An open-label, randomized, Phase 3 clinical trial of IO102-IO103 in combination with pembrolizumab versus pembrolizumab alone in patients with previously untreated, unresectable, or metastatic (advanced) melanoma	IMMUNOTP. ONCOLOGICA	Maio
KRT-232-103	A Phase 1b/2, Open-Label Study Evaluating the Safety and Efficacy of KRT-232 in Patients with p53 Wild-Type (p53WT) Merkel Cell Carcinoma (MCC) Who Have Failed Anti-PD-1 or Anti-PD-L1 Immunotherapy, or in Combination with Avelumab in MCC Patients Who Are Anti-PD-1 or Anti-PD-L1 Treatment Naïve	IMMUNOTP. ONCOLOGICA	Maio
MADAM	Studio osservazionale retrospettivo-prospettico su pazienti italiani con melanoma trattati in setting adiuvante nella Cohort MAP per valutare la sopravvivenza libera da recidiva e la sopravvivenza globale	IMMUNOTP. ONCOLOGICA	Di Giacomo
MK 0482-001	A Phase 1b, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-0482 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors.	IMMUNOTP. ONCOLOGICA	Maio
MK 3475-B98	A Phase 1b/2 Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With Investigational Agents for the Treatment of Participants With PD-1/L1-refractory Extensive-Stage Small Cell Lung Cancer in Need of Second-Line Therapy (KEYNOTE-B98)	IMMUNOTP. ONCOLOGICA	Maio
MK 3475-B99	A Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Etoposide and Cisplatin or Carboplatin for the First-Line Treatment of Participants With	IMMUNOTP. ONCOLOGICA	Maio

	Extensive-Stage Small Cell Lung Cancer (KEYNOTE-B99)		
MK 7339-002	A Phase 2 Study of Olaparib Monotherapy in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer	IMMUNOTP. ONCOLOGICA	Maio
MK1308-001	Safety Pharmacokinetics PK and Efficacy of MK 1308 in Combination with Pembrolizumab in Advanced Solid Tumors	IMMUNOTP. ONCOLOGICA	Maio
MK3475-02A (Substudy 02A)	Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma	IMMUNOTP. ONCOLOGICA	Maio
MK3475-02B (Substudy 02B)	Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma	IMMUNOTP. ONCOLOGICA	Maio
MK3475-02C (Substudy 02C)	Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy	IMMUNOTP. ONCOLOGICA	Maio
MK3475-02D	A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma (KEYMAKER-U02): Substudy 02D	IMMUNOTP. ONCOLOGICA	Maio
MK-3475-054	Adjuvant Immunotherapy With Anti-PD-1 Monoclonal Antibody Pembrolizumab (MK- 3475) Versus Placebo After Complete Resection of High-risk Stage III Melanoma: A	IMMUNOTP. ONCOLOGICA	Maio

	Randomized, Double- Blind Phase 3 Trial of the EORTC Melanoma Group		
MK-3475-158	A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors (KEYNOTE-158)	IMMUNOTP. ONCOLOGICA	Maio
MK3475-495	A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab-(MK-3475, SCH 900475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (KEYNOTE-495; KeyImPaCT)	IMMUNOTP. ONCOLOGICA	Maio
MK3475-587	A Multicenter, Open Label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial	IMMUNOTP. ONCOLOGICA	Maio
MK3475-716	Adjuvant Therapy With Pembrolizumab Versus Placebo in Resected High-risk Stage II Melanoma: A Randomized, Double-blind Phase 3 Study (KEYNOTE-716)	IMMUNOTP. ONCOLOGICA	Maio
MK3475-913	A Phase 3 Open-label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) as First-line Therapy in Participants With Advanced Merkel Cell Carcinoma (KEYNOTE-913)	IMMUNOTP. ONCOLOGICA	Maio
MK7339-007	A Phase 2 Study of Pembrolizumab in Combination with Olaparib in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer	IMMUNOTP. ONCOLOGICA	Maio

MK7684A-010	A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study of Adjuvant MK-7684A (Vibostolimab With Pembrolizumab) Versus Adjuvant Pembrolizumab in Participants With High-risk Stage II-IV Melanoma (KEYVIBE-010)	IMMUNOTP. ONCOLOGICA	Maio
MK7902-003	A phase 3, randomized, placebo-controlled trial to evaluate the safety and efficacy of Pembrolizumab plus Levatinib vs Pembrolizumab alone as first line in patients with advanced	IMMUNOTP. ONCOLOGICA	Maio
MK7902-005	A Multicenter, Open-label Phase 2 Study of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) in Previously Treated Subjects with Selected Solid Tumors	IMMUNOTP. ONCOLOGICA	Maio
MO43576	A randomized, multicenter, openlabel cross-over study to evaluate patient and healthcare professional reported preference for subcutaneous atezolizumab compared with intravenous formulation in patients with non-small cell lung cancer	IMMUNOTP. ONCOLOGICA	Maio
NIBIT-M2	A randomized, Phase III study of Fotemustine versus the Combination of Fotemustine and Ipilimumab and the Combination of Ipilimumab and Nivolumab in Patients with Metastatic Melanoma with brain metastasis	IMMUNOTP. ONCOLOGICA	Di Giacomo
NIBIT-M4	A phase 1b, open-label, dose escalation study investigating different doses of SGI-110 in combination with ipilimumab in unresectable or metastatic melanoma patients	IMMUNOTP. ONCOLOGICA	Di Giacomo
NIBIT-ML1	A randomized, run-in, phase II study of nivolumab with ipilimumab and guadecitabine or nivolumab combined with ipilimumab in melanoma and NSCLC patients resistant to anti PD1/PD-L1	IMMUNOTP. ONCOLOGICA	Di Giacomo

PH-L19IL2TNF-02/15	A pivotal Phase III, open label, randomized, controlled multicenter study of the efficacy of L19IL2/L19TNF neoadjuvant intratumoral treatment followed by surgery versus surgery alone in clinical stage IIIB and III C melanoma patients	IMMUNOTP. ONCOLOGICA	Maio
SC104	A phase 2, open-label, single-arm, multicenter study of SOT101 in combination with pembrolizumab to evaluate the efficacy and safety in patients with selected advanced/refractory solid tumors	IMMUNOTP. ONCOLOGICA	Maio
SGNVLA-005	Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors	IMMUNOTP. ONCOLOGICA	Maio
SRP-21C101	A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of ADU-1604, an Anti-CTLA-4 Antibody, in Adults With Metastatic Melanoma	IMMUNOTP. ONCOLOGICA	Maio
THOR 42756493BLC3001	A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR Gene Aberrations)	IMMUNOTP. ONCOLOGICA	Maio
Trizell	A Phase 3, Open-Label, Randomized, Parallel Group Study to Evaluate the Efficacy and Safety of Intrapleural Administration of Adenovirus-Delivered Interferon Alpha-2b (rAd-IFN) in Combination with Celecoxib and Gemcitabine in Patients with Malignant Pleural Mesothelioma	IMMUNOTP. ONCOLOGICA	Maio
V937-011	A Phase 2, Randomized Clinical Study of Intravenous or Intratumoral Administration of V937 in Combination with Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants with Advanced/Metastatic Melanoma	IMMUNOTP. ONCOLOGICA	Maio



V940-001	A Phase 3, Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-Risk Stage II-IV Melanoma (INTerpath-001)	IMMUNOTP. ONCOLOGICA	Maio
W00090GE101	An open label, multicentre, phase I study to evaluate the impact of moderate and severe hepatic impairments on the pharmacokinetics and safety of encorafenib in combination with binimetinib in adult patients with unresectable or metastatic BRAF V600-mutant solid tumors.	IMMUNOTP. ONCOLOGICA	Maio
W00090GE303	Adjuvant Encorafenib & Binimetinib vs. Placebo in Fully Resected Stage IIB/C BRAF V600E/K Mutated Melanoma: a Randomized Triple-blind Phase III Study in Collaboration With the EORTC Melanoma Group	IMMUNOTP. ONCOLOGICA	Maio
XB002-101	A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 as Single-Agent and Combination Therapy in Subjects With Inoperable Locally Advanced or Metastatic Solid Tumors	IMMUNOTP. ONCOLOGICA	Maio
FIL-QoL- ELDIND	Qualità di vita di pazienti anziani con linfoma non-Hodgkin a basso grado trattati con immunoterapia o immunochemioterapia e/o radioterapia	EMATOLOGIA	Bocchia
VYXEOS	Formulazione liposomiale di daunorubicina e citarabina (Vyxeos, CPX-351) per il trattamento delle forme di Leucemia Acuta Mieloide terapia correlate o Leucemia Acuta Mieloide con alterazioni mielodisplatiche: studio retrospettivo Multicentrico sui dati di efficacia e sicurezza	EMATOLOGIA	Bocchia

HCL - PG05	VEMURAFENIB + RITUXIMAB COME ALTERNATIVA NON-CHEMIOTERAPICA A CLADRIBINA SEGUITA DA RITUXIMAB MRD-GUIDATO NEL TRATTAMENTO DI PRIMA LINEA DELLA LEUCEMIA A CELLULE CAPELLUTE (HCL): STUDIO CLINICO DI FASE-2, MULTICENTRICO E RANDOMIZZATO	EMATOLOGIA	Bocchia
ES_DLBCL	Raccolta dati retrospettiva sul trattamento dei pazienti affetti da Linfoma B-diffuso a grandi cellule con malattia localizzata	EMATOLOGIA	Bocchia
SI_MCL	Raccolta dati retrospettiva sul trattamento dei pazienti affetti da Linfoma mantellare	EMATOLOGIA	Bocchia
GAZEBO Trial	An open-label, randomized phase III trial comparing local radiotherapy alone or combined with Obinutuzumab in early stage Follicular Lymphoma: the GAZEBO Trial from the Fondazione Italiana Linfomi -	EMATOLOGIA	Bocchia
INCB88888-040	Multicenter Prospective Real-world Observational cohort study to evaluate the effectiveness of tafasitamab in combination with lenalidomide followed by tafasitamab monotherapy in relapsed or refractory diffuse large B-cell lymphoma non-transplant eligible patients in Italy (PRO-MIND).	EMATOLOGIA	Bocchia